UCART123 – Clinical Trial Open to Recruitment

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed in our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

UCART123

  1. SUB-TYPE OF MDS:Patients newly diagnosed with CD123 positive adverse genetic risk acute myeloid leukaemia (AML), including patients with CD123 positive AML secondary to MDS
  2. SEVERITY OF MDS: AML
  3. NAME OF DRUG: UCART targeting CD123 positive leukaemia cells
  4. Aims and benefits: This is a phase 1 first in human study to determine the safety and effectiveness of multiple infusions of UCART123 (specially engineered T-cells that target leukaemia cells that express CD123).

  1. Basic inclusion criteria:
    • Aged 18 - 65 years
    • Weight ≥42 kg
    • Patients must have received 1 of the 2 trial-stipulated induction chemotherapy regimens
    • Availability of a suitable sibling or unrelated HLA matched donor
    • ECOG performance status of 0 or 1
  2. Basic exclusion criteria:
    • Patients with ≥ 20% blasts in bone marrow after 1 or 2 courses of standard intensive induction chemotherapy
    • Patients with AML transformed from previously diagnosed myeloproliferative disorder
    • Patients with APL
    • Evidence of CNS leukaemia on CSF examination
    • AML relapsing after first complete remission
    • Prior allogeneic stem cell transplant
    • Therapy-related AML
    • Favourable or intermediate risk AML
    • Prior gene or experimental cellular therapy
    • HIV/HBV/HCV Infection
  3. Trial sites/locations and name of physician in charge of trial (none are currently recruiting):
    • Kings College Hospital

Please read information and always discuss trial information with your own physician.

Free donations by shopping

Sign-up to Download our Free Patient Handbook!

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

MDS UK Patient Support Group will use the information you provide on this form to be in touch with you and to provide updates.